Введение. Данные клинических наблюдений свидетельствуют, что опухоли яичника и некоторые другие разновидности карцином демонстрируют выраженный ответ на производные платины или схожие препараты, если у пациентки есть наследственные мутации BRCA1/2 других генов ДНК-репарации. Изучение BRCA1/2-негативных раков (РЯ), которые продемонстрировали хороший платиносодержащую терапию, представляется перс...

Recent data suggests that treating patients with pancreatic cancer that express mutations in BRCA1, BRCA2, and PALB2 with chemotherapy which targets the DNA repair defect in these cells, such as platinum based therapies or PARPi [poly (ADP-ribose) polymerase inhibitor], may be more beneficial in these patients. Moreover, further data also indicates the promise of combining PARPi with convention...

The National Cancer Institute estimates that 12% of all women (about 1 in 8) will be diagnosed with breast cancer and 3% will be diagnosed with ovarian cancer throughout their lifetime.1,2 5-10% of all breast and ovarian cancers diagnosed are hereditary. Risk factors for hereditary breast and ovarian cancers include a family history with highly penetrant mutations in genes such as BRCA1 and BRC...

PURPOSE This study sought to assess the prevalence of common germline mutations in several genes engaged in the repair of DNA double-strand break by homologous recombination in patients with triple-negative breast cancers and hereditary non-triple-negative breast cancers. Tumors deficient in this type of DNA damage repair are known to be especially sensitive to DNA cross-linking agents (e.g., p...